rs80358711
From SNPedia
| Orientation | plus |
| Stabilized | plus |
| Geno | Mag | Summary |
|---|---|---|
| (A;C) | 6 | BRCA2 variant considered pathogenic for breast cancer |
| (C;C) | 0 | common in clinvar |
| (C;G) | 6 | BRCA2 variant considered pathogenic for breast cancer |
| Make rs80358711(G;G) |
| Reference | GRCh38 38.1/141 |
| Chromosome | 13 |
| Position | 32339244 |
| Gene | BRCA2 |
| is a | snp |
| is | mentioned by |
| dbSNP | rs80358711 |
| dbSNP (classic) | rs80358711 |
| ClinGen | rs80358711 |
| ebi | rs80358711 |
| HLI | rs80358711 |
| Exac | rs80358711 |
| Gnomad | rs80358711 |
| Varsome | rs80358711 |
| LitVar | rs80358711 |
| Map | rs80358711 |
| PheGenI | rs80358711 |
| Biobank | rs80358711 |
| 1000 genomes | rs80358711 |
| hgdp | rs80358711 |
| ensembl | rs80358711 |
| geneview | rs80358711 |
| scholar | rs80358711 |
| rs80358711 | |
| pharmgkb | rs80358711 |
| gwascentral | rs80358711 |
| openSNP | rs80358711 |
| 23andMe | rs80358711 |
| SNPshot | rs80358711 |
| SNPdbe | rs80358711 |
| MSV3d | rs80358711 |
| GWAS Ctlg | rs80358711 |
| Max Magnitude | 6 |
rs80358711, also known as S1630X, c.4889C>G and p.Ser1630Ter, is a variant in the BRCA2 gene considered pathogenic for breast cancer in ClinVar.
23andMe name for c.4889C>G: i5009395
| ClinVar | |
|---|---|
| Risk | rs80358711(A;A) rs80358711(G;G) |
| Alt | rs80358711(A;A) rs80358711(G;G) |
| Reference | Rs80358711(C;C) |
| Significance | Pathogenic |
| Disease | Familial cancer of breast Breast-ovarian cancer Hereditary breast and ovarian cancer syndrome Hereditary cancer-predisposing syndrome not provided |
| Variation | info |
| Gene | BRCA2 |
| CLNDBN | Familial cancer of breast Breast-ovarian cancer, familial 2 Hereditary breast and ovarian cancer syndrome Hereditary cancer-predisposing syndrome not provided |
| Reversed | 0 |
| HGVS | NC_000013.10:g.32913381C>A; NC_000013.10:g.32913381C>G |
| CLNSRC | ClinVar Ambry Genetics |
| CLNACC | RCV000044511.2, RCV000257254.1, RCV000044512.3, RCV000077340.6, RCV000131080.2, RCV000255089.2, |
